The present invention relates to a compound of formula (I) based on enamine derivatives and used as organic hole conductors or hole transporting material in an optoelectronic or photoelectrochemical device. The present invention relates to the hole transporting compounds based on enamine derivatives for efficiency perovskite or dye sensitized solar cells and optoelectronic devices, organic light-emitting diode (OLED), field-effect transistors (FET).

The invention features compounds and pharmaceutical compositions having anti-inflammatory properties. Also provided are methods of using the compounds or compositions of the invention for treating an inflammatory disorder in a subject in need thereof.

The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of Aβ42 oligomers in a subject. It further provides a method of reducing formation of or disrupting Aβ42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.

The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of Aβ42 oligomers in a subject. It further provides a method of reducing formation of or disrupting Aβ42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.

There are disclosed deuterated 2C—X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT.sub.2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT.sub.2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

There are disclosed deuterated 2C—X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT.sub.2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT.sub.2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

##STR00001##

The present disclosure provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of Aβ42 oligomers in a subject. It further provides a method of reducing formation of or disrupting Aβ42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition. One such compound is a compound of formula 120: ##STR00001##

The present disclosure provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of Aβ42 oligomers in a subject. It further provides a method of reducing formation of or disrupting Aβ42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition. One such compound is a compound of formula 120: ##STR00001##

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.